Must have hemoglobin (Hgb) ? 9.0 g/dL within 14 days prior to randomization. Must not have required transfusion of red blood cells within 1 week of baseline Hgb assessment.
Hgb ? 10 g/dL
Hemoglobin (Hgb) >= 8 g/dL (with or without transfusion support)
Patients with Hgb > 8.0 g/dl (transfusion allowed)
Hgb < 10 g/dL
Hemoglobin (HGB) > 8.0 gm/dL (patients may be transfused to achieve this HGB level);
Additional Laboratory Requirements ANC ?1.0 x 109/L Hgb ?8 g/dL(transfusion permitted) Platelet count ?50.0 x 109/L
Hgb > 8.0 (transfusion allowed)
Hemoglobin (HgB) > 9 g/dL. Must not have required transfusion of red blood cells within 1 week of baseline Hgb assessment.
Hemoglobin (Hgb) >= 9 g/dL (with/without transfusion)
Hgb ? 9 g/dL
Hgb > 8.0 (transfusion allowed)
Hemoglobin (Hgb) < 8 mg/dl, per PI discretion if thought to be related to underlying myeloma
Hemoglobin (Hgb) >= 9 g/dL (more than 48 hours post-completion of blood transfusion)
Hemoglobin (Hgb) >= 9 g/dL (in absence of blood transfusion).
Within 4 weeks of day 1: Hemoglobin (HgB) >= 10.0 gr/dL independent of transfusion
Hemoglobin (Hgb) ? 9 g/dL obtained ? 14 days prior to randomization; patient may receive transfusion as needed
Hemoglobin (Hgb) >= 9 g/dL or >= 5.6 mmol/L without (w/o) transfusion within 7 days of assessment.
Hemoglobin (Hgb) >= 9 g/dL; (last transfusion cannot be within 7 days of trial initiation)
Hgb >= 10 g/dL ((within 16 days before starting therapy)
HGB of > 10 g/L
PART 2 GROUP 2A INCLUSION CRITERIA: Hgb >= 8 g/dL (may receive RBC transfusion)
PART 2 GROUP 3 INCLUSION CRITERIA: Hgb >= 8 g/dL (may receive RBC transfusion)
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Hemoglobin (Hgb) < 9 mg/dl (transfusion permitted to achieve this)
EXCLUSION CRITERIA FOR TNBC: Hgb < 9 mg/dl (transfusion permitted to achieve this)
PRIOR TO CELL PROCUREMENT: Hemoglobin (Hgb) ? 8.0 g/dL (transfusion independent for 2 weeks prior to enrollment)
Hgb ? 9 g/dL
Within 14 days prior to study entry: Hemoglobin (Hgb) > 9.0 g/dL (with or without transfusion)
TREATMENT: Hgb > 8.0 (transfusion allowed)
Hgb > 8.0
Hemoglobin (HgB) > 9.0 g/dL; NOTE: subjects may not have had a transfusion within 7 days of registration
Within 14 days of study drug(s) initiation: Hemoglobin (Hgb) >= 10 g/dL with no blood transfusion in the past 14 days.
EXCLUSION CRITERIA FOR TREATMENT: Hgb less than or equal to 8 g/dL
Hemoglobin (Hgb) >= 8 g/dl (transfusion acceptable)
HGB ?10 g/dl and not transfusion dependent
Hgb > 9 g/dL
Hgb ?9 g/dL
Within 14 days of study start: Hemoglobin (Hgb) >= 9 g/dL (may transfuse if clinically indicated)
Hemoglobin (Hgb) > 9 g/dL (can be achieved with transfusion)
Hemoglobin (Hgb) >= 8 gm/dL (transfusion independent)
Hemoglobin (Hgb) >= 9.0 g/dL (no red blood cell [RBC] transfusion within past 14 days)\r\n* Hgb >= 8.0 g/dL for patients with anemia associated disease
Hemoglobin (Hgb) >= 9 g/dL (which may be post transfusion)
Hemoglobin (Hgb) >= 9.5 g/dL (transfusion before treatment is allowable if more than 3 days prior to study start)
Hemoglobin (Hgb) >= 9.0 g/dL (90 g/L) without blood transfusion within 7 days
Hemoglobin (Hgb) >= 9 mg/dL (which may be post transfusion)
Hemoglobin (Hgb) >= 9 g/dL may be supported by transfusion and/or hematopoetic growth factors
Hemoglobin (Hgb) >= 9.0 g/dL (transfusion allowed), within 14 days of registration
Hemoglobin (Hgb) >= 8.5 g/dL (transfusion or erythropoietin-like substances not permitted prior to baseline evaluation)
HgB < 9 g/dL
HGB >9.0 g/dL
Hemoglobin (Hgb) ? 9.0 g/dL within 14 days prior to randomization. Must not have required transfusion within 1 week of baseline Hgb assessment.
Does the subject have a Hgb ? 10 g/dL?
Hgb > 7.5 g/dl (without transfusion within 7 days)
Hgb ? 9 g/dL
Required prior to infusion of ATLCAR.CD30 cells: Hgb >= 8g/dL without transfusion support over preceding 5 days
Hemoglobin (Hgb) > 10.0 g/dL with no blood transfusion in the past 28 days
Hemoglobin (hgb) ? 8.0 g/dL (may be supported with transfusion)
Hemoglobin (Hgb) >= 9 g/dL (90 g/L); < 9 g/dL (< 90 g/L) is acceptable if Hgb is corrected to >= 9 g/dL (90 g/L) as by growth factor or transfusion prior to PET scan, obtained within 14 days prior to PET scan
Hemoglobin (HGB) > 8.0 gm/dl
Hemoglobin >= 9.0 gm/dL
Within 30 days prior to enrollment: Hemoglobin > 11 gm/dl
Hemoglobin >= 9 gm/dl, performed within 14 days of treatment initiation
Hemoglobin (Hgb) > 8.0 gm/dL
PHASE I: Hemoglobin >= 9 gm/dL
PHASE IB: Hemoglobin >= 9 gm/dL
Hemoglobin >= 9.0 gm/dL
PART I: Hemoglobin >= 9.0 gm/dL
PART II: Absolute hemoglobin >= 9.0 gm/dL
Hemoglobin >= 10 gm/dL
Hemoglobin >= 9 gm/dL
Hemoglobin (Hgb) > 7.5 gm/dL
Hemoglobin >= 8.0 gm/dL
Hemoglobin > 8 gm/dL
Hemoglobin > 9.0 gm/dL
Hemoglobin (Hgb) > 8.0 gm/dL
Hemoglobin level <9.0 gm/L
Hemoglobin >= 9 gm/dl
Hemoglobin level >= 8.0 gm/dL on screening complete blood count
Hemoglobin < 9.0 gm/dL (SI units gm/L)
Hemoglobin (Hgb) >= 9.0 gm/dl
Hemoglobin >= 8 gm/dL (Group I)
Hemoglobin if anemia attributed to KS, KSHV-MCD, or KICS >= 7 gm/dL, otherwise >= 8 gm/dL (Group II)
Creatinine of less than or equal to 1.7 gm/dL
Hemoglobin of 9 gm/dL or more
Within 6 weeks of day 1: Hemoglobin (HgB) >= 9.0 gm/dL
Hemoglobin (Hgb) >= 10.0 gm/dl within 14 days of study entry
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Hemoglobin >= 9 gm/dl
Hemoglobin >= 10 gm/dL prior to biopsy
d. Hemoglobin ? 9 gm/dL.
Hemoglobin > 8.0 gm/dL, transfusion allowed
At least one laboratory abnormality probably or definitely attributed to KSHV-MCD\r\n* Anemia (hemoglobin [Hgb] [men] =< 12.5 gm/dL, Hgb [women] =< 11 gm/dL)\r\n* Thrombocytopenia (=< 130,000/mm^3)\r\n* Hypoalbuminemia (< 3.4 g/dL)
Hemoglobin >= 9 gm/dl
Hemoglobin >= 9.0 gm/dL (may be a post transfusion value)
Hemoglobin <9 gm/dl for males; < 8.5 gm/dl for females.
serum M-protein ?1 gm/dL (?10 gm/L).
Hemoglobin >= 9 gm/dl
Hemoglobin >= 10.0 gm/dL
Hemoglobin > 8.0 gm/dL, transfusion allowed
Hemoglobin >= 8.0 gm/dL within 28 days prior to registration.
Hemoglobin < 10 gm/dL.
Hemoglobin >= 8 gm/dl
Hemoglobin >= 8.0 gm/dL
Hemoglobin >= 8.0 gm/dL
Performed within 14 days prior to study: Hemoglobin > 10 gm/dl
Hemoglobin >= 9 gm/dL (transfusion permitted)
Hemoglobin (Hgb) >= 9.0 gm/dL
Creatinine of less than or equal to 1.7 gm/dL
Hemoglobin of 8 gm/dL or more
Creatinine of less than or equal to 1.7 gm/dL
Hemoglobin of 8 gm/dL or more
Hemoglobin >= 9 gm/dL (may be corrected by transfusion)
Hemoglobin >= 9.0 g/dL (SI units gm/L)
Hemoglobin >= 10 gm/dL
Hemoglobin >= 8 gm/dl (untransfused)
Creatinine =< 1.5 gm/dL
Hemoglobin >= 9.0 gm/dL
Hemoglobin > 9.0 gm/dL
Hemoglobin >= 9.0 gm/dL
Hemoglobin >= 10 gm/dL
Hemoglobin >= 10.0 gm/dL
Hemoglobin < 8.0 gm/dL
Hemoglobin >= 90 gm/L
Hemoglobin > 9 gm/dl
Hemoglobin of >= 8.0gm/dL
Hemoglobin (Hgb) >= 9 gm/dL
Hemoglobin > 8gm/dL (transfusions permitted)
Hemoglobin (Hgb) >8.0gm/dL
Hemoglobin >= 9 gm/dL
Hemoglobin (Hgb) >= 9 gm/dL (unless due to bone marrow infiltration by tumor in which case Hgb > 8 gm/dL)
Hemoglobin >= 9 gm/dL
Hemoglobin (HGB) >= 8 gm/dL
Hemoglobin > 8.0 gm/dl
Hemoglobin >= 10 gm/dl
Hemoglobin > 10 gm/100ml
Hemoglobin >= 9 gm/dl
A hemoglobin > 10 gm/dl
Hemoglobin >= 8 gm/dl
Hemoglobin >= 8.0 gm/dL
Hemoglobin >= 9.0 gm/dl
Creatinine < 1.5 gm/dL
Hemoglobin (HGB) >= 9 gm/dL
Hemoglobin >= 9 gm/dL
Hemoglobin < 9 gm/dL
Hemoglobin < 9.0 gm/dL (SI units gm/L)
Hemoglobin >= 6 gm/dL
Hemoglobin >= 9.0 gm/dL (transfusion permitted)
Hemoglobin >= 10.0 gm/dl
Hemoglobin < 8 gm/dl
Serum creatinine (Cr) =< 2 gm/dL
Hemoglobin: 7.0-16.1 gm/dL
Hemoglobin >= 9 gm/dL
Patients must have hemoglobin level >= 11gm/dl (age adjusted if appropriate) provided by the reference laboratory performing the test
Within 14 days prior to study entry: Hemoglobin > 9 gm/dl
Hemoglobin ? 9 gm/dL
Hemoglobin >= 9 gm/dL
Hemoglobin >= 9.0 gm/dL
Hemoglobin >= 9 gm/dL
Hemoglobin >= 9 gm/dL
Hemoglobin >= 9 gm/dL
Hemoglobin >= 9 gm/dL
Hemoglobin >= 9.0 gm/dL
Hemoglobin >= 9 gm/dL
Hemoglobin >= 10 gm/dL, performed within 28 days prior to registration
Hemoglobin >= 9 gm/dL
Hemoglobin >= 10.0 g/dL and no blood transfusions in the 28 days prior to entry/randomization
Hemoglobin >= 8 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 8 g/dL) (within 14 days of treatment initiation)
Procurement: Hemoglobin (Hgb) > 8.0 g/dl (transfusions allowed)
Hemoglobin levels at the time of or within 7 days prior to transfusions must have been ? 9.0 g/dL for the transfusions to qualify as required for the purpose of providing evidence of transfusion-dependent anemia.
Hemoglobin (Hgb) >= 10 g/dL (may be achieved with erythropoietin agents; no blood transfusions in the 28 days prior to entry)
PROCUREMENT: Hemoglobin (Hgb) > 8.0 (transfusions allowed)
TREATMENT: Hgb > 8.0 g/dL (transfusions allowed)
Hemoglobin >= 9.0 gm/dL (may receive RBC transfusions)
Hemoglobin >= 8 g/dL\r\n* Note: Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier
Hemoglobin >= 9 g/dL performed within 30 days prior to the date of registration; no transfusions and erythropoietin supplementation permitted within the last 3 months
Hemoglobin greater than 9.0 mg/dl (transfusions are permitted to achieve baseline hemoglobin level), within 14 days prior to registration
Hemoglobin >= 8.0 g/dL (may receive transfusions)
Hemoglobin >= 8 g/dl (may receive transfusions)
INCLUSION CRITERIA FOR STRATUM C: Hemoglobin >= 8 g/dl (may receive transfusions)
Hemoglobin >= 8 g/dL (transfusions are permissible)
Hemoglobin >= 9 g/dL (transfusions allowed)
Hemoglobin >= 9 g/dL, with no blood transfusions in the 28 days prior to study entry
Hemoglobin >= 9 g/dL (transfusions permitted)
Within 14 days prior to registration: Hemoglobin >= 8.0 mg/dl (transfusions are permitted to achieve baseline hemoglobin level)
Hemoglobin >= 8 g/dL; RBC transfusions and use of G-CSF will be allowed in order to meet eligibility parameters (unless dysfunction is secondary to lymphoma involvement)
Hemoglobin ? 8.0 g/dL (may receive transfusions)
Hemoglobin ? 9 g/dL (transfusions are allowed)
Hemoglobin >= 9 g/dl (no blood transfusions within 4 weeks prior to enrollment)
hemoglobin ? 9.0 g/dL (transfusions permissible)
Hemoglobin (Hgb) >= 9 g/dL without transfusions
CAPMATINIB INCLUSION CRITERIA: Hemoglobin >= 9 g/dL (transfusions are allowed)
CERITINIB INCLUSION CRITERIA: Hemoglobin >= 8 g/dL (transfusions are allowed)
ENTRECTINIB INCLUSION CRITERIA: Hemoglobin >= 8 g/dL (transfusions are allowed)
Hemoglobin > 8g/dL (may receive transfusions).
Hemoglobin (Hgb) >= 9 g/dL (transfusions allowed)
Hemoglobin >= 9.0 g/dL and no blood transfusions in the 28 days prior to enrollment
INCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: Hemoglobin >= 9.0 g/dL (transfusions are permitted)
PROCUREMENT: Hemoglobin (Hgb) > 8.0 (transfusions allowed)
Hemoglobin >= 8 g/dl (may receive transfusions)
Hemoglobin (Hgb) ? 9 g/dL. NOTE: subject must not have received any growth factor or blood transfusions within 14 days prior to the hematology values obtained at screening. Subjects requiring transfusions to meet eligibility criteria are not eligible.
Hemoglobin at least 8.0 grams per deciliter (g/dL) at Baseline (blood transfusions are allowed during the screening period to correct hemoglobin values less than 8.0 g/dL) As blood transfusions are permitted to meet the hemoglobin criteria, participants requiring transfusion must not be known to be refractory to red blood cell or platelet transfusions.
Hemoglobin (Hgb) >= 9 g/dL without transfusions
Hemoglobin >= 8 g/dL (may receive transfusions)
To be performed within 28 days prior to day 1 of protocol therapy: Hemoglobin (Hgb) >= 8 g/dL without transfusions
Hemoglobin >= 10 g/dL (transfuse as necessary to raise levels, no transfusions within 7 days of start)
Hemoglobin greater than 8 g/dl (patients may receive transfusions to meet this parameter)
Hemoglobin (Hgb) >= 9.0 g/dL (transfusions allowed)
Hemoglobin >= 9 g/dL\r\n* Blood transfusions are allowed at any time during the screening, treatment or follow-up period, according to the center recommendations
Hemoglobin >= 90 g/L\r\n* Blood transfusions are allowed at any time during the screening, treatment or follow-up period, according to the center recommendations
Hemoglobin >= 9 g/dL (prior to transfusions)
Hemoglobin >= 9 g/dL (transfusions are acceptable)
Hemoglobin >= 10 g/dL (transfusions are not permissible)
Hemoglobin >= 8 g/dL (may receive transfusions)
Hemoglobin >= 9 g/dL (transfusions allowed)
Hemoglobin >= 9.0 g/dL (not requiring transfusions within the past 2 weeks)
Hemoglobin >= 8 g/dL\r\n* Transfusions and erythropoietin supplementation permitted
Hemoglobin (Hgb) greater than or equal to 9 g/dL (transfusions are allowed)
Hemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)
Hemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)
Hemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeks
Hemoglobin: >= 8 g/dL (no transfusions within 7 days) within 30 days prior to registration
Within 8 weeks of randomization: Hemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)
Hemoglobin (Hgb) >= 9 g/dL without transfusions
Participants requiring blood transfusions to maintain hemoglobin (Hgb) eligibility
TREATMENT: Hemoglobin greater than 8 g/dl (patients may receive transfusions to meet this parameter)
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Hemoglobin >= 8 g/dl (may receive transfusions)
NON-PROGRESSED DIPG (STRATUM 2): Hemoglobin >= 8 g/dl (may receive transfusions)
Hemoglobin >= 8 g/dL (transfusions are permissible)
Hemoglobin ? 9 g/dL (with no RBC transfusions within 7 days of Screening)
Hemoglobin >= 8.0 g/dL (may receive transfusions)
Hemoglobin >= 5.59 mmol/L or 9 g/dL; up to 5% deviation is tolerated; transfusions and growth factors are allowed
Hemoglobin (Hgb) >= 9 g/dL without transfusions
Hematologic: Absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L, hemoglobin ? 9 g/dL (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. The first dose of study drug must not begin until 5 days after the erythrocyte transfusion);
Hemoglobin >= 9.0 g/dL (not requiring transfusions within the past 2 weeks)
Hemoglobin (Hb) >= 9g/dL (women) or >= 11g/dL (men) (supportive transfusions will be allowed during induction and maintenance phases to maintain these levels)
Hemoglobin >= 8 g/dL (with transfusions)
Hemoglobin ? 9 g/dL (transfusions are allowed)
Hemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeks
Hemoglobin > 10 g/dL (transfusions allowed)
Hemoglobin greater than 8g/dl (patients may receive transfusions to meet this parameter)
Hemoglobin (Hgb) >= 9 g/dL without transfusions
Hemoglobin > 8 g/dL (international system [SI] units: 80 g/L); patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier than the day after the erythrocyte transfusion
Hemoglobin > 8 mg/dl; Physician can maintain a patient's hemoglobin with the use of erythropoietin or transfusions (prophylactic use of G-CSF [filgrastim] is not permitted)
Hemoglobin >= 9 g/dL (transfusions and/or erythropoietin are permitted)
Hemoglobin ?9 g/dL (?90 g/L) Note that transfusions are allowed to meet the required hemoglobin level
INCLUSION CRITERIA FOR SECOND-LINE THERAPY: Patients may have a transfusion of red blood cells to meet the hemoglobin requirement
INCLUSION CRITERIA FOR THIRD-LINE THERAPY: Patients may have a transfusion of red blood cells to meet the hemoglobin requirement
Absolute neutrophil count (ANC) 1500/mm^3 within 3 weeks prior to study registration; blood transfusion to meet the inclusion criteria will not be allowed
Blood transfusion to meet the inclusion criteria will be allowed
Absolute neutrophil count ? 1,500. Blood transfusion to meet the inclusion criteria not be allowed.
Absolute neutrophil count (ANC) >= 1500/mm^3 is necessary; blood transfusion to meet the inclusion criteria will not be allowed
Platelet count > 100000/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Hemoglobin (Hb) > 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowed
Absolute neutrophil count (ANC) >= 1500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Blood transfusion to meet the inclusion criteria will be allowed
Absolute neutrophil count (ANC) >= 1,500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Blood transfusion to meet the inclusion criteria will not be allowed
Note: supportive care (e.g. transfusion of red blood cells) is allowed to meet eligibility criteria
Platelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Hemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowed
Absolute neutrophil count (ANC) >= 1500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Platelet count ? 100,000 /mm3, hemoglobin (Hb) ? 9 g/dL, absolute neutrophil count (ANC) ? 1500/mm3. Blood transfusion to meet the inclusion criteria will not be allowed.
Platelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Hemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowed
Absolute neutrophil count (ANC) >= 1500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Platelet count >= 100000/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Hemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowed
Absolute neutrophil count (ANC) >= 1500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Blood transfusion to meet the inclusion criteria will be allowed
Platelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criterion will not be allowed
Hemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criterion will not be allowed
Absolute neutrophil count (ANC) >= 1500/mm^3; blood transfusion to meet the inclusion criterion will not be allowed
Blood transfusion to meet the following laboratory requirements will not be allowed
Platelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Hemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowed
Absolute neutrophil count (ANC) 1500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
Blood transfusion to meet the inclusion criteria will not be allowed
Hemoglobin (Hgb) >= 9 g/dl
Hemoglobin (Hgb) > 8.0 g/dL =< 2 weeks prior to randomization
Hemoglobin (HgB) >= 9.0 g/dL
Hemoglobin (HgB) >= 9.0 gr/dL
Hemoglobin (Hgb) >= 8.5
Hemoglobin (Hgb) >= 8 g/dl
Hemoglobin (Hgb) ? 8 g/dL
Hemoglobin (Hgb) ? 80 g/L
Hemoglobin (Hgb) < 9 g/dL
Hemoglobin (Hgb) ? 9 g/dL;
Hemoglobin (Hgb) > 10 g/dL within 14 days of starting cycle 1 day 1 treatment
Hemoglobin (Hgb) >= 9.0 g/dl
Hemoglobin (Hgb) >= 8 g/dL
Hemoglobin (HGB) >= 9 g/dL
Hemoglobin (HgB) > 8.0
Hemoglobin (Hgb) > 8.0
Hemoglobin (Hgb) ? 8.0 g/dL, stable for ? 1 week
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) > 9 g/dL, at the screening visit
Hemoglobin (Hgb) >= 10.0 g/dL
Hemoglobin (Hgb) <9 g/dL
Hemoglobin (Hgb) >= 8 g/dL
Hemoglobin (Hgb) > 9 g/dL.
INCLUSION - TREATMENT: Hemoglobin (Hgb) ? 9.0 g/dl
Hemoglobin (Hgb) > 9 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Anemia (hemoglobin [Hgb] < 10 g/dL)
Hemoglobin (Hgb) >= 9 g/dL.
Hemoglobin (Hgb) >= 8.5 g/dl
Hemoglobin (Hgb) >= 8 g/dL
Hemoglobin (HgB) >= 9 g/dL compatible for surgery
Hemoglobin (HgB) < 10 g/dL
Hemoglobin (Hgb) > 8 g/dL
Hemoglobin (Hgb) ? 9.0 g/dL
Hemoglobin (Hgb) =< 10.0 or
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) >= 9 g/dL.
Hemoglobin (Hgb) < 8 mg/dl
Hemoglobin (HgB) >= 9.0 g/dL
Hemoglobin (Hgb) >= 9 g/dL (within 16 days before starting therapy)
Hemoglobin (HGB) >= 10 g/dl
Hemoglobin (Hgb) > 8.0 g/dL
Hemoglobin (HgB) >= 9.0 g/dL
Hemoglobin (Hgb) >= 9 g/dl
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) >= 10 g/dl within 30 days of enrollment to study
Hemoglobin (Hgb) > 8.5 g/dL
Hemoglobin (Hgb) > 9.0 g/dL, within 14 days prior to treatment
Hemoglobin (Hgb) >= 9 g/dL.
Hemoglobin (Hgb) >= 8 g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) ? 9 g/dL
Hemoglobin (HGB) < 8 g/dL
Hemoglobin (Hgb) >= 8 gr/dL
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) > 8 g/dl
Hemoglobin (Hgb) ? 90 g/L (9 g/dL).
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (HgB) >= 9.0 g/dL
Hemoglobin (Hgb) >= 8 g/dL
Within 3 months of registration: Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) > 10 within 30 days of consent
Hemoglobin (Hgb) > 9 within 45 days of consent
Hemoglobin (HgB) >= 9 g/dL
AT THE TIME OF INFUSION: Hemoglobin (Hgb) ? 8.0
Hemoglobin (Hgb) >= 9 g/dL
TREATMENT: Hemoglobin (Hgb) > 8.0 g/dL
Hemoglobin (Hgb) <9 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) >= 8
Hemoglobin (Hgb) >= 8 g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) greater than 10 g/L
Hemoglobin (Hgb) > 9 g/dL
Within 30 days of first vaccination: Hemoglobin (Hgb) >= 10 g/dl
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (HgB) > 8.0
Hemoglobin (Hgb) >= 9
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) >= 10 g/dl
Hemoglobin (HgB) >= 9.0 g/dL
Hemoglobin (Hgb) >= 8.5 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) >= 10 g/dl
Hemoglobin (HGB) >= 9 g/dL
Hemoglobin (Hgb) < 8 g/dL
Hemoglobin (Hgb) > 8.0
Hemoglobin (Hgb) > 9 g/dL
Hemoglobin (Hgb) >= 9.0 g/dl
Hemoglobin (Hgb) >= 9 g/dl
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (HgB) >= 9 g/dL for mono-therapy
Hemoglobin (Hgb) ? 9 g/dL
Hemoglobin (Hgb) ? 9 g/dL
Hemoglobin (HgB) >= 9.0 g/dL
Hemoglobin (Hgb) less than or equal to 8 g/dL
Hemoglobin (Hgb) > 8 g/dL
Hemoglobin (HgB) > 9.0 g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) >= 8 g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) < 9 g/dL
Hemoglobin (Hgb) > 9 g/dL
Hemoglobin (Hgb) > 10
Hemoglobin (HgB) >= 9.0 g/dL
Hemoglobin (Hgb) >= 8.0 g/dL
Hemoglobin (Hgb) >= 9.0 g/dl
Hemoglobin (Hgb) > 8.0
Anemia (hemoglobin [Hgb] < 10 g/dL)
Hemoglobin (Hgb) ? 90 g/L,
Hemoglobin (Hgb) ? 9.0 g/dL
Hemoglobin (Hgb) ? 9 g/dL
Hemoglobin (Hgb) ? 9 g/dl
Hemoglobin (Hgb) ? 9 g/dL.
Hemoglobin (Hgb) ? 9 g/dl
Hemoglobin (HgB) >= 9
Hemoglobin (Hgb) > 9 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) > 9 g/dL
Hemoglobin (Hgb) > 8.0 g/dL
Hemoglobin (Hgb) > 8.0
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) >= 8 g/dL
Hemoglobin (HgB) ?9 g/dL.
Hemoglobin (Hgb) >= 10 g/dL (within 16 days before starting therapy)
Hemoglobin (Hgb) > 9
Hemoglobin (Hgb) > 9 g/dl
Hemoglobin (HGB) >= 10 g/dl
Hemoglobin (Hgb) > 10 g/dL
Hemoglobin (Hgb) > 10 g/dL
Hemoglobin (HgB) >= 10.0 g/dL
Hemoglobin (Hgb) >= 8 g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
hemoglobin (Hgb) > 9.9 g/dL
Hemoglobin (HgB) >= 9.0 g/dL
Hemoglobin (HGB) >= 8 g/dL
Hemoglobin (Hgb) >= 10 g/dl
Hemoglobin (Hgb) >= 10 g/dL (within 16 days before starting therapy)
Hemoglobin (Hgb) >= 8 g/dl
Hemoglobin (Hgb) >= 8.5 g/dL
Hemoglobin (Hgb) >= 9 g/dl
Hemoglobin (Hgb) ? 10 g/dl
Hemoglobin (Hgb) ? 10 g/dl.
Hemoglobin (Hgb) ? 9.0 g/dL
Hemoglobin (Hgb) < 7.0
Hemoglobin (Hgb) >= 9.0 g/dl
Hemoglobin (hgb) =< 10.0 or
Hemoglobin (HgB) >= 9.0 mg/dL
Hemoglobin (Hgb) > 8.0 g/dl
Hemoglobin (Hgb) >= 9g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) > 9 g/dL
Hemoglobin (Hgb) >= 9 g/dl
Hemoglobin (Hgb) ? 9.0 g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) > 8.0
Hemoglobin (Hgb) ? 9 g/dL.
Hemoglobin (Hgb) < 9 g/dL
Hemoglobin (Hgb) ?10 g/dL
Hemoglobin (HgB) > 9.0 g/dL
Hemoglobin (Hgb) >= 10 g/dL
Hemoglobin (Hgb) >= 10 g/dL
Hemoglobin (Hgb) >= 9.0 g/dl
Hemoglobin (Hgb) ? 9.0 g/dL
SELUMETINIB ARM: Hemoglobin (Hgb) < 9.0 g/dL
Hemoglobin (HgB) >= 8.0 g/dL
Hemoglobin (Hgb) >= 9 g/L
Hemoglobin (Hgb) >= 10 g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) ? 9.0 g/dL;
Hemoglobin (Hgb) ? 9 g/dL.
Hemoglobin (HgB) >= 9 g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) ? 9 g/L
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) >= 9.0 g/dL
Hemoglobin (Hgb) ? 9 g/dL.
Hemoglobin (Hgb) ? 8.0 g/dL at Baseline (within 24 hours prior to surgical procedure).
Hemoglobin (Hgb) > 9 g/dL
Hemoglobin (Hgb) ? 8.0 g/dL
Hemoglobin (Hgb) ? 9 g/dL
Hemoglobin (Hgb) > 9 g/dL
Hemoglobin (Hgb) > 9 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (HgB) > 8.5 g/dL
Hemoglobin (Hgb) ?9.5 g/dl
Hemoglobin (HgB) > 9.0 g/dL
Hemoglobin (Hgb) >= 9.0 g/dl
Hemoglobin (Hgb) > 9.0 gms/dl
Hemoglobin (Hgb) > 8.0 g/dl
Hemoglobin (Hgb) >= 8 g/dL
Hemoglobin (Hgb) > 9 g/dL
Hemoglobin (Hgb) >= 9 g/dL
Severe anemia with hemoglobin (HGB) < 10
Hemoglobin (Hgb) ? 9.0 g/dL
Hemoglobin (HgB) >= 9.0 g/dL
Hemoglobin (Hgb) ?>= 8.0 g/dL
Hemoglobin (Hgb) >= 9.0
Hemoglobin (Hgb) >= 9 g/dL
Hemoglobin (Hgb) > 8.0
Hemoglobin (Hgb) > 8.0 g/dL
Hemoglobin (Hgb) >= 10 g/dl within 90 days of enrollment
Hemoglobin (Hgb) >= 8.0g/dL
Hemoglobin (Hgb) ? 8 g/dL.
Hemoglobin (Hgb) ? 10 g/dl
Hemoglobin (Hgb) > 8.0
Hemoglobin (hgb) > 10 G/dL
Hemoglobin (HgB) > 9 mg/dL
Hemoglobin >= 9 g/dL, patients may receive transfusion to meet criterion within 30 days of day 1 of study
Hemoglobin > 9 g/dL, transfusion permitted
Hemoglobin ?9.0 g/dL without transfusion within the 2 weeks prior to Day 1.
Hemoglobin >= 8.0 g/dl (without transfusion within the previous 7 days)
Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell transfusion is permitted)
Hemoglobin >= 10 g/dL without transfusion within 4 days prior to enrollment
Hemoglobin >= 10 g/dL with no blood transfusion in the past 28 days, =< 5 days prior to C1D1
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration.
Within 28 days prior to administration of study treatment: Hemoglobin >= 10 g/dL with no pack red blood cell transfusion in the past 28 days
Hemoglobin >= 8.0 g/dl, with or without transfusion
Hemoglobin 9 g/dl or more; (transfusion permitted)
Hemoglobin 9 g/dl or more; (transfusion permitted)
Hemoglobin >= 9g/dL (transfusion permitted)
Hemoglobin >= 9.0 g/dL (prior transfusion permitted) within 14 days of cycle 1 day 1
Hemoglobin >= 10.0 g/dL with no blood transfusion within 28 days of starting treatment
Hemoglobin >= 8 (with or without transfusion)
Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days, measured within 28 days prior to administration of study treatment
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
Hemoglobin (no transfusion within prior 7 days) >= 9.0 g/dL
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
Hemoglobin >= 10 g/dL (no blood transfusion in the 28 days prior to entry [olaparib guidelines])
Hemoglobin < 8.0 g/dL (transfusion permitted at least 7 days prior to baseline)
Hemoglobin >= 8.0 g/dL (transfusion permitted)
PHASE I: Hemoglobin >= 9 g/dl, and no blood transfusion within 4 weeks; OR > 10 g/dL, and no blood transfusion within 2 weeks
PHASE II SCLC: Hemoglobin >= 9 g/dl, and no blood transfusion within 4 weeks; OR > 10 g/dL, and no blood transfusion within 2 weeks
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
Hemoglobin >= 9 g/dL without transfusion within 7 days prior to enrollment
Hemoglobin >= 9 g/dL qualifications (transfusion permitted)
Hemoglobin >= 9.0 g/dL with last transfusion at least 14 days before day 1 of study drug
Hemoglobin greater than 8.0 g/dL (transfusion independent; no transfusion for >= 7 days prior to study enrollment)
Hemoglobin >= 9.0 mg/dL without transfusion in 2 prior weeks
Hemoglobin >= 8 g/dL (transfusion permitted)
Hemoglobin >= 9.0 g/dL (after transfusion if required)
Hemoglobin >= 9 g/dL; continuation of erythropoietin products is permitted; hemoglobin must be stable above 9 g/dL for at least 2 weeks without blood transfusion to maintain hemoglobin level
Hemoglobin ? 9 g/dL (without transfusion for at least one month)
Hemoglobin > 8.0 mg/dL (without transfusion in the preceding 7 days)
Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days.
Within 28 days prior to administration of study treatment: Hemoglobin ? 10.0 g/dL with no blood transfusion in the past 28 days
Within 14 days prior to first dose of study drug treatment: Hemoglobin >= 9 g/dL without transfusion in the previous week
Hemoglobin (no transfusion within prior 7 days) >= 9.0 g/dL
Hemoglobin >= 9 g/dL without transfusion in the preceding 7 days
Hemoglobin >= 10 g/dL with no blood transfusion in the past 28 days
Measured within 28 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days
Within 28 days prior to administration of therapy: Hemoglobin >= 10 g/dL with no blood transfusion within 28 days of initiation of therapy
Hemoglobin > 8 gm/dL without transfusion and off erythropoietin for 14 days or Aranesp for 21 days
Hemoglobin ?9.0 g/dL without transfusion within the 2 weeks prior to Day 1.
Hemoglobin >10.5 g/dL (without erythropoietin or blood transfusion within the last 2 weeks)
Patients must have adequate organ and marrow function measured within 28 days prior to administration of ABT-888 as defined below:\r\n* >= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 days
Hemoglobin >= 9 g/dL; erythropoietin and transfusion support is permitted provided treatments are not required more than every 8 weeks; hemoglobin must be stable above or equal to 9 g/dL for at least 2 weeks prior to day 1 of study drug without blood transfusion to maintain hemoglobin level
Hemoglobin >= 9 g/dL continuation of erythropoietin products is permitted obtained =< 7 days prior to randomization; hemoglobin must be stable >= 9 g/dL >= 14 days without blood transfusion to maintain hemoglobin level
Hemoglobin >= 9.0 g/dL (transfusion permitted)
Hemoglobin ? 8 g/dL (transfusion is permitted to fulfill this criterion)
Within 30 days prior to initiation of protocol treatment: Hemoglobin >= 9.0 g/dL (after transfusion if required)
Hemoglobin >= 8.0 g/dL with no blood transfusion in the past 28 days.
Hemoglobin > 9 g/dL (prior transfusion permitted)
Hemoglobin >= 9 g/dL (blood transfusion permitted to attain this value)
Measured within 28 days prior to administration of ABT-888: >= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 days
Hemoglobin >= 9 g/dl (transfusion permitted)
Hemoglobin >= 9 g/dL (without transfusion within 7 days of assessment)
Hemoglobin 9.0 g/dL (transfusion to meet this criterion is permitted)
Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell transfusion is permitted)
Hemoglobin ? 9.0 g/dL (in case of transfusion stable for ?14 days prior to treatment start)
Hemoglobin ?8 g/dL [transfusion permitted]
Hemoglobin ?8 g/dL [transfusion permitted]
Hemoglobin >= 9 g/dL; subjects may not have had a transfusion within 7 days of screening assessment
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
Hemoglobin > 9.0 g/dL (no transfusion permitted within 1 week)
Hemoglobin >= 7g/dL (transfusion permitted)
Patients must have >= 10.0 g/dL hemoglobin (Hb) and no blood transfusion in the past 28 days to receive veliparib